 CAMBRIDGE, Mass., Feb. 24, 2021 GLOBE NEWSWIRE -- Surface Oncology Nasdaq: SURF, a clinical-stage immuno-oncology company developing next-generation therapies targeting the tumor microenvironment, today announced that Rob Ross, M.D., incoming chief executive officer, will participate in the following virtual investor conferences: 